Portfoliotracker

Autolus Therapeutics plc

AUTL · NASDAQGS · Healthcare Biotechnology 0/100 E

1,140 $
▼ −0,030 (−2,56 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 12:26
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score0 / 100 Market cap303 mil. $ P/E– Forward P/E-2,0 P/S2,2 P/B11,1 EV/EBITDA– Dividend yield– FCF yield-59,38 % EPS-0,96 $ Net margin-186,4 % Return on equity-174,9 % Beta2,35 Debt / equity14,49
52-week range 1,07 to 2,58
3-month average volume2,1 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Employees
752
Country
United Kingdom
Fiscal year end
31. 12.
Data since
22. 6. 2018

Explore further

Similar companies ALLOBCYCCABAMGTXCTMX

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account